AI designs custom vaccines to fight lung cancer
NCT ID NCT07285434
Summary
This early-stage study is testing a personalized vaccine, Microlyvaq™, for people with advanced non-small cell lung cancer (NSCLC). The vaccine is custom-made for each patient using AI to analyze their specific tumor. It is given alongside standard chemotherapy and immunotherapy (pembrolizumab). The goal is to train the patient's immune system to better recognize and attack their cancer, aiming for stronger and longer-lasting control of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Biogenea Pharmaceuticals Ltd
Thessaloniki, Macedonia, 54627, Greece
Conditions
Explore the condition pages connected to this study.